NCT00256204View on ClinicalTrials.gov

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

1,174

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

June 30, 2009

Conditions
Parkinson's Disease
Interventions
DRUG

Rasagiline Mesylate

tablet, 1mg once daily

DRUG

Rasagiline Mesylate

tablet, 2mg once daily

OTHER

Placebo

Placebo

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00256204 - A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease | Biotech Hunter | Biotech Hunter